Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.

about

Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.

Item

http://www.wikidata.org/entity/Q47420701

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Bevacizumab in combination wit ...... ncer: A network meta-analysis.

@en

Bevacizumab in combination wit ...... ncer: A network meta-analysis.

@nl

type

Item

label

Bevacizumab in combination wit ...... ncer: A network meta-analysis.

@en

Bevacizumab in combination wit ...... ncer: A network meta-analysis.

@nl

prefLabel

Bevacizumab in combination wit ...... ncer: A network meta-analysis.

@en

Bevacizumab in combination wit ...... ncer: A network meta-analysis.

@nl

P1476

Bevacizumab in combination wit ...... ancer: A network meta-analysis

@en

P2093

Fangfang Gao

http://www.w3.org/2001/XMLSchema#string

Shen Zhao

http://www.w3.org/2001/XMLSchema#string

Yaxiong Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Practical methods for incorporating summary time-to-event data into meta-analysis

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

P304

1676-1688

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1002/IJC.31175

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

Zhonghan Zhang

Li Zhang

P577

2017-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29171009

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab